腎素(REN)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Renin (REN) ,etc. by FLIA (Flow Luminescence Immunoassay)
angiotensinogenase
（注：?jiǎn)未位鞙y(cè)多因子不超過(guò)8個(gè)指標(biāo) ）
- 編號(hào)ULMA889Ra
- 物種Rattus norvegicus (Rat，大鼠) 相同的名稱(chēng)，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)3.5h
- 檢測(cè)范圍0.98-1000pg/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.327 pg/mL.
- 樣本類(lèi)型serum, plasma and other biological fluids
- 下載 英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格 8指標(biāo)數(shù) 7指標(biāo)數(shù) 6指標(biāo)數(shù) 5指標(biāo)數(shù) 4指標(biāo)數(shù) 3指標(biāo)數(shù) 2指標(biāo)數(shù)1指標(biāo)數(shù)
- 價(jià)格 ¥ 1281 ¥ 1330 ¥ 1404 ¥ 1502 ¥ 1601 ¥ 1749 ¥ 1970 ¥ 2463 添加到價(jià)格計(jì)算器 計(jì)算器
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷(xiāo)商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)腎素(REN)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)，經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的腎素(REN)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 81-94 | 90 |
| EDTA plasma(n=5) | 79-92 | 87 |
| heparin plasma(n=5) | 99-105 | 102 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線(xiàn)性
在定值血清及血漿樣本內(nèi)加入適量的腎素(REN)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線(xiàn)性范圍即為稀釋后樣本中腎素(REN)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 88-97% | 99-105% | 88-95% | 81-89% |
| EDTA plasma(n=5) | 80-91% | 93-105% | 82-96% | 81-101% |
| heparin plasma(n=5) | 94-105% | 97-104% | 83-95% | 95-103% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品、樣本、磁珠）標(biāo)準(zhǔn)品或樣本100μL及磁珠10μL，
37°C酶標(biāo)板振蕩器孵育90分鐘；
3. 磁吸甩干，加檢測(cè)溶液A100μL，37°C酶標(biāo)板振蕩器孵育60分鐘；
4. 磁吸洗板3次；
5. 加檢測(cè)溶液B100μL，37°C振動(dòng)孵育30分鐘；
6. 磁吸洗板3次；
7. 加鞘液100μL，旋渦震蕩2分鐘后讀數(shù)。
實(shí)驗(yàn)原理
將腎素(REN)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體包被于磁珠，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠，其中的腎素(REN)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的腎素(REN)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體，將未結(jié)合的生物素化抗體洗凈后，加入PE標(biāo)記的親和素，再次徹底洗滌后即可上機(jī)讀數(shù)。MFI值和樣品中的腎素(REN)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)呈正相關(guān)。
贈(zèng)品
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Rattus norvegicus (Rat，大鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| URPA889Ra02 | 腎素(REN)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPA889Ra01 | 腎素(REN)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAA889Ra02 | 腎素(REN)多克隆抗體 | WB; IHC; ICC; IP. |
| UPAA889Ra01 | 腎素(REN)多克隆抗體 | WB |
| ULAA889Ra71 | 腎素(REN)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| UMAA889Ra21 | 腎素(REN)單克隆抗體 | WB |
| UMAA889Ra23 | 腎素(REN)單克隆抗體 | WB; IHC; ICC; IP. |
| UMAA889Ra22 | 腎素(REN)單克隆抗體 | WB; IHC; ICC; IP. |
| USEA889Ra | 腎素(REN)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| USCA889Ra | 腎素(REN)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| ULMA889Ra | 腎素(REN)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Hypertension | Prenatal overexposure to glucocorticoids programs renal 11β-hydroxysteroid dehydrogenase type 2 expression and salt-sensitive hypertension in the rat [PubMed: 21045727] |
| The Journal of Physiology | Recombinant human erythropoietin in humans down-regulates proximal renal tubular reabsorption and causes a fall in glomerular filtration rate [Physoc: 194241] |
| The Journal of Physiology | Erythropoietin down‐regulates proximal renal tubular reabsorption and causes a fall in glomerular filtration rate in humans [PubMed: 20724370] |
| Pathobiology | Anti-Angiotensin and Hypoglycemic Treatments Suppress Liver Metastasis of Colon Cancer Cells [Karger: 000330169] |
| Journal of Cardiovascular Pharmacology | The Angiotensin Receptor Blocker, Azilsartan Medoxomil (TAK-491), Suppresses Vascular Wall Expression of Plasminogen Activator Inhibitor Type-I Protein Potentially Facilitating the Stabilization of Atherosclerotic Plaques [LWW: 08000] |
| Kidney International | Multiple and large simple renal cysts are associated with prehypertension and hypertension. [Pubmed: 23389415] |
| Human Physiology | Estimation of the parameters of the renin-angiotensin-aldosterone system, water-electrolyte metabolism, and endothelial function in newborns of women with chronic hypertension [Springer:Source] |
| Journal of Pharmacological Sciences | Organ-Specific Activation of the Gastric Branch of the Efferent Vagus Nerve by Ghrelin in Urethane-Anesthetized Rats [Pubmed:24366191] |
| Liver International | VSL#3 probiotic treatment decreases bacterial translocation in rats with carbon tetrachloride-induced cirrhosis [Pubmed:24750552] |
| Gynecological Endocrinology | Immunological and hemostasiological disorders in women with ovarian hyperstimulation syndrome [Pubmed:25200828] |
| Oxidative Medicine and Cellular Longevity | Age-Associated Changes in the Vascular Renin-Angiotensin System in Mice [Pubmed:27200147] |
| PLoS One | Ablation of Potassium-Chloride Cotransporter Type 3 (Kcc3) in Mouse Causes Multiple Cardiovascular Defects and Isosmotic Polyuria [Pubmed:27166674] |
| PLOS?ONE | Reduced?Expression?of the?Extracellular?Calcium-Sensing?Receptor?(CaSR) Is?Associated?withActivation?of the?Renin-Angiotensin?System?(RAS) to Promote Vascular Remodeling in the Pathogenesis of Essential Hypertension. [pubmed:27391973] |
| Heart Lung Circ. | Efficacy and Safety of Renal Sympathetic Denervation on Dogs with Pressure Overload-Induced Heart Failure. [pubmed:27555054] |
| European Journal of Pharmaceutical Sciences | Sacubitril/valsartan (LCZ696) Significantly Reduces Aldosterone and Increases cGMP Circulating Levels in a Canine Model of RAAS Activation [Doi: 10.1101/435560] |
| Nutrition | Gut Dysbiosis Contribute to High Fructose Induced Salt Sensitive Hypertension In Sprague-Dawley Rats [] |
| ACTA PHARMACOLOGICA SINICA | The vascular endothelial growth factor trap aflibercept induces vascular dysfunction and hypertension via attenuation of eNOS/NO signaling in mice [33303990] |
| Hypertens Res | Association of Ang-(1¨C7) and des-Arg 9 BK as new biomarkers of obesity and cardiometabolic risk factors in adolescents [33568792] |
| Phosphorylation of ?21-integrin in juxtaglomerular cells helps control blood pressure during the progression of diabetic nephropathy [] | |
| Bedeutung des intrarenalen Renin-Angiotensin-Systems f¨1r die Entwicklung der chronischen Nierenkrankheit [] |
